Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPAC-6 in resected pancreatic ductal adenocarcinoma
NCT05314998Phase 3Recruiting
- Start
- Aug 2026
- Primary completion
- Apr 2033
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 3 trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, folinic acid, fluorouracil, gemcitabine in pancreatic ductal adenocarcinoma (PDAC). Started Aug 2026; status: recruiting.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfolinic acidfluorouracilgemcitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05314998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05314998.